הלוואות ואשראי לטווח ארוך של החברה biomx.com (PHGE)

BiomX Inc. (PHGE) specializes in developing bacteriophage-based drugs, with the company's financial stability directly dependent on the outcome of current research. Risks are linked to the potential failure of lung drug trials and significant losses, which are partially offset by grants. This chart illustrates a market valuation of debt obligations at 0.00, highlighting that business success depends on the fight against resistant infections and the stability of bio-mixture production.

For BiomX Inc. (PHGE), which develops highly specialized phage cocktails against resistant infections, the size of the firm's long-term borrowings reflects the volume of liabilities with a maturity of more than one year. This indicator measures the long-term credit load, allowing investors to assess capital resilience in servicing debt while financing costly R&D developments, which determines the company's financial viability during periods of asset consolidation.